









Markets
/
Stocks
/
nasdaq-tbph
/

Theravance Biopharma Inc

TBPH

15.080USD

-0.110-0.72%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

487.08MMarket Cap

7.17P/E TTM



Theravance Biopharma Inc

15.080

-0.110-0.72%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Theravance Biopharma Inc

Currency: USD Updated: 2026-03-27

Key Insights

Theravance Biopharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.17.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Theravance Biopharma Inc's Score

Industry at a Glance

Industry Ranking

29 / 157

Overall Ranking

101 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Theravance Biopharma Inc Highlights

StrengthsRisks

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 87.14% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 7.17, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 49.90M shares, decreasing 7.35% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 532.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.59.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

16.333

Target Price

+7.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Theravance Biopharma Inc is 8.37, ranking 61 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 45.89M, representing a year-over-year increase of 144.70%, while its net profit experienced a year-over-year increase of 493.02%.

Score

Industry at a Glance

Previous score

8.37

Change



Financials

9.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.34

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Theravance Biopharma Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Theravance Biopharma Inc is 7.25, ranking 84 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 7.17, which is 742.26% below the recent high of 60.35 and 354.56% above the recent low of -18.24.

Score

Industry at a Glance

Previous score

7.25

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 29/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Theravance Biopharma Inc is 7.14, ranking 113 out of 157 in the Pharmaceuticals industry. The average price target is 27.00, with a high of 42.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

7.14

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

16.333

Target Price

+7.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Theravance Biopharma Inc

TBPH

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Theravance Biopharma Inc is 7.30, ranking 20 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 18.61 and the support level at 12.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.34

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.627

Neutral

RSI(14)

44.202

Neutral

STOCH(KDJ)(9,3,3)

78.132

Neutral

ATR(14)

0.448

Low Volatility

CCI(14)

96.703

Neutral

Williams %R

28.511

Buy

TRIX(12,20)

-0.922

Sell

StochRSI(14)

67.321

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

15.042

Buy

MA10

14.523

Buy

MA20

14.423

Buy

MA50

17.505

Sell

MA100

17.823

Sell

MA200

15.287

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Theravance Biopharma Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 98.47%, representing a quarter-over-quarter increase of 5.14%. The largest institutional shareholder is The Vanguard, holding a total of 2.37M shares, representing 4.64% of shares outstanding, with 11.41% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Madison Avenue Partners LP

9.51M

Weiss Asset Management

7.46M

Newtyn Management, LLC

4.95M

BlackRock Institutional Trust Company, N.A.

3.23M

-1.92%

Irenic Capital Management LP

2.76M

The Vanguard Group, Inc.

Star Investors

2.21M

+2.51%

D. E. Shaw & Co., L.P.

1.21M

+20.72%

Acadian Asset Management LLC

1.09M

+252.95%

Winningham (Rick E)

1.23M

-5.16%

State Street Investment Management (US)

1.06M

+1.96%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Theravance Biopharma Inc is 6.12, ranking 59 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.18. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Theravance Biopharma Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.